

19 February 2021

**Scancell Holdings plc**  
("Scancell" or the "Company")

**Director Dealing**

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that Vulpes Life Sciences Fund ("Vulpes"), a person closely associated with Martin Diggle, Non-Executive Director, has sold 400,000 ordinary shares of 0.1 pence each in Scancell Holdings plc ("Ordinary Shares") at an aggregated price of 27.25 pence per Ordinary Share.

Following the sale of Ordinary Shares, Vulpes has a total interest of 116,179,029 shares representing 14.3% of the total voting rights of the Company.

**For further information, please contact:**

<b>Scancell Holdings plc</b> Dr John Chiplin, Executive Chairman Dr Cliff Holloway, CEO	+44 (0) 20 3727 1000
<b>Panmure Gordon (UK) Limited</b> Freddy Crossley/Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	+44 (0) 20 7886 2500
<b>FTI Consulting</b> Simon Conway/Natalie Garland-Collins	+44 (0) 20 3727 1000

**About Scancell**

Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody<sup>®</sup>, Moditope<sup>®</sup> and AvidiMab<sup>™</sup>, with four products in multiple cancer indications and development of a vaccine for COVID-19.

ImmunoBody<sup>®</sup> vaccines target dendritic cells and stimulate both CD4 and CD8 T cells with the ability to identify, target and eliminate cancer cells. These cancer vaccines have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. The Directors believe that this platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

- SCIB1, Scancell's lead product, is being developed for the treatment of metastatic melanoma. In a Phase 1/2 clinical trial, survival with SCIB1 treatment appears superior to historical survival rates, with 14 of 16 resected patients receiving 2-4 mg doses of SCIB1 surviving for more than five years (as reported in February 2018).
- SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours.

DNA vaccine against COVID-19: As research data emerges, it is becoming increasingly clear that the induction of potent and activated T cells may play a critical role in the development of long-term immunity and clearance of virus-infected cells. Initial research is underway and Scancell anticipates initiating a Phase 1 clinical trial known as COVIDITY during 2021.

Moditope<sup>®</sup> represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). Examples of such modifications are citrullination, an enzyme-based conversion of arginine to citrulline, and homocitrullination (or carbamylation), in which lysine residues are converted to homocitrulline. Expression of peptides containing these modifications have been demonstrated to induce potent CD4 cytotoxic t cells to eliminate cancer. Previous pre-clinical studies have demonstrated that conjugation of these Moditope<sup>®</sup> peptides to Amplivant<sup>®</sup> enhances anti-tumour immune

responses 10-100 fold and resulted in highly efficient tumour eradication, including protection against tumour recurrence.

- Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide each conjugated to Amplivant®. Vimentin and enolase peptides are highly expressed in triple negative breast, ovarian, head and neck, and renal cancer, as well as many other cancers. The Company continues to progress the Modi-1 Phase 1/2 clinical trial for regulatory submission to start the planned clinical study in the UK in the first half of 2021.

AvidiMab™ has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody (mAb) including those being developed for autoimmune diseases, as well as cancer. Scancell's development pipeline includes mAbs against specific tumour-associated glycans (TaGs) with superior affinity and selectivity profiles, that have now been further engineered using the Company's AvidiMab™ technology; this confers the Scancell anti-TaG mAbs with the ability to directly kill tumour cells. The Company has entered into three non-exclusive research agreements with leading antibody technology companies to evaluate the Company's anti-TaG mAbs including those enhanced with the AvidiMab™ technology.

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	Martin Diggle
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Person closely associated with Vulpes Life Science Fund
b)	Initial notification/Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Scancell Holdings plc
b)	LEI	2138008RXEG856SNP666
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.1 pence each
b)	Identification Code	GB00B63D3314
c)	Nature of the transaction	Sale of shares
d)	Price(s) and volume(s)	200,000 ordinary shares at 27 pence per ordinary share; 200,000 ordinary shares at 27.5 pence per ordinary share;
e)	Aggregated information - Aggregated volume - Aggregated price	400,000 Ordinary Shares 27.25 pence per Ordinary Share
f)	Date of the transaction	18 February 2021
g)	Place of the transaction	London Stock Exchange, AIM